Tuesday, August 26, 2025

Sundial Growers: Canaccord Raises Price Target Due To Strong Balance Sheet

Sundial Growers (NASDAQ: SNDL) reported its second quarter financial results on August 12. The company announced net revenues of $9.15 million, slightly lower than their $9.89 million first quarter revenue. The company, once again, had negative gross margins as the company’s cost of sales was $9.5 million. The company had a flat Adjusted EBITDA number, down from the $3.3 million in the first quarter but they did postan improved net loss.

One of the 5 analysts that cover the firm increased their 12-month price target on Sundial, bringing the consensus average up to $0.69, from $0.60. Out of the 5 analysts, 4 have hold ratings and 1 has a sell rating. The street high sits at $0.80 from ATB Capital Markets, while the lowest comes in at $0.45.

Canaccord Genuity was the single firm to raise its 12-month price target. They raised it to $0.75 from $0.70 and reiterated their hold rating on the name saying that the cannabis operations remained flat while its investments are starting to bear fruit.

For the second quarter, Sundial’s top-line game was in line with Canaccord’s estimates while everything else basically missed. For the top-line, Canaccord says that this shows that Canada is still in a challenging operating environment but the revenue beat shows that Sundial is making headway into transitioning to higher-margin products rather than the value segment.

For specific revenue segments, Sundial’s oil segment grew 60%, while its vape segment dropped 70%. Management has reiterated their plan of grabbing core/premium segments with a new 22%+ THC strain releasing by the end of the year. Canaccord says, “We continue to believe that management’s decision to limit discount offerings (a segment that continues to capture a majority of the market) will negatively impact brand awareness in the short term.”

The company ended the quarter with $760 million in total cash and equivalents. This sets the company up to keep on finding attractive investments, which has earned the company $3.7 million of net profits.

Below you can see Canaccord’s updated full year 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

What Happens If Silver Finally Breaks $50? | Gary Thompson – Silver47

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Organigram: Haywood Raises Estimates Betting On Increased Market Share

On January 11th, Organigram Holdings (TSX: OGI) issued its second fiscal quarter earnings for 2022....

Saturday, January 15, 2022, 11:09:00 AM

Filo Mining: BMO Lifts Price Target To $28 Following Assay Results

This past week, Filo Mining Corp. (TSX: FIL) reported its updated assay results from three...

Sunday, April 24, 2022, 05:01:00 PM

BMO Reiterates $10 Price Target On Kinross Gold Following Russian Asset Sale

On April 5th, Kinross Gold (TSX: K) announced the sale of its Russian assets, with...

Saturday, April 9, 2022, 03:03:00 PM

BMO Upgrades AngloGold To Outperform, Raises Price Target To $36

This morning, BMO Capital Markets upgraded AngloGold Ashanti (NYSE: AU) to outperform and upgraded their...

Tuesday, December 8, 2020, 11:34:03 AM

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM